Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease
With the assistance of RAS inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists, finerenone effectively reduces urinary protein and improves the inflammatory response, demonstrating relatively manageable safety in real-world DKD treatment. The patients with macroalbuminuria may experience greater benefits.
Authors
- Lina Wang (ORCID: https://orcid.org/0000-0003-1033-7072)
- YiMeng Li
- Shan‐Shan Dong (ORCID: https://orcid.org/0000-0001-6976-4576)
- Jia Tao Song (ORCID: https://orcid.org/0000-0002-0122-8360)
- Jing Gao (ORCID: https://orcid.org/0000-0002-4447-8749)
- Yuqing Guo (ORCID: https://orcid.org/0000-0002-2989-3178)
- Dan Wang (ORCID: https://orcid.org/0009-0006-8685-2635)
- AiGe Yang
- Yan Kang (ORCID: https://orcid.org/0000-0003-4968-1217)
- XinJu Jia
Institutions
- Hebei Medical University (CN)
- First Affiliated Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1371/journal.pone.0329965
- Citations
- 1
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Department of Finance of Hebei